• Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites
• New formulation to accommodate higher patient volumes at reduced per-dose costs
• Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast cancer patients
• The global cancer immunotherapy market is expected to be valued at nearly $125 billion by the end of 2024
• Breast cancer remains one of the most commonly diagnosed cancers among women globally, with 2.1 million cases expected in 2018

Battling a cancer prognosis is often referred to as “fighting the good fight,” but it’s a tough, uphill battle for many patients combating advanced breast cancer. The need for effective, lasting breast cancer treatment is urgent, the Cancer Research Institute (http://ibn.fm/bGdDk) states in an article titled ‘How is Immunotherapy Changing the Outlook for Patients with Breast Cancer’. As an immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is dedicated to developing the first off-the-shelf, personalized immunotherapy targeting the unmet needs of advanced breast cancer patients.

BriaCell’s lead cancer drug candidate – Bria-IMT – has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who matched the Bria-IMT HLA types. Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. BriaCell recently announced the imminent clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://ibn.fm/wiZwo). Bria-IMT is currently being tested in a phase I/IIa clinical trial with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)], listed on ClinicalTrials.gov as NCT03328026.

“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients. This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients,” Dr. Bill Williams, BriaCell’s president and CEO, stated in a news release (http://ibn.fm/76eLc). “The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective.”

The global cancer immunotherapy market is expected to jump from $37.5 billion in 2015 to $124.9 billion by the end of 2024, maintaining a compound annual growth rate of 14.6 percent during the forecast period from 2016 to 2024, according to Transparency Market Research (http://ibn.fm/W5dpd). The global cancer immunotherapy market is expected to witness a spike in demand for immune checkpoint inhibitors due to their high success rates and improved overall efficiency, the report states. Globally, more than two million new breast cancer cases were estimated to have been diagnosed during 2018.

BriaCell is on the cutting edge of cancer treatment with its proprietary, effective and safe immunotherapy applications, Williams explained during a featured interview on Uptick Newswire’s Stock Day Podcast. Williams shared his enthusiasm for the company’s technological advancements in battling advanced breast cancer as he reviewed progress made and plans for the company’s future (http://ibn.fm/WwYTT).

“We’ve dosed over 20 patients now with Bria-IMT. It has been very safe and well tolerated,” Williams said in the interview. “We’ve seen this strong anti-tumor response in the patients who match Bria-IMT at HLA alleles, so we are very excited about the prospects of these findings.”

BriaCell recently presented a poster at a 2019 Keystone Symposia scientific conference, held January 20-24 at the Fairmont Hotel in Vancouver, British Columbia. The presentation highlighted BriaCell’s recent clinical and research-focused development of Bria-IMT and BriaDX programs (http://ibn.fm/fUIMc). BriaDX is the corresponding companion diagnostic test that helps identify those patients most likely to benefit from treatment with Bria-IMT and Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy, which is currently under development with plans to enter the clinic in 2H2019.

BriaCell management also attended Biotech Showcase 2019, an important investor conference that took place January 7-9 at the Hilton Union Square in San Francisco, California.

For more information, visit the company’s website at www.BriaCell.com

• Leader in technological innovation and world-class customer service
• Launched Netevia in-app payments software development kit
• Focused on the creation of a unified global transaction acceptance ecosystem

In a fiercely competitive environment, Net Element Inc. (NASDAQ: NETE) stands out for its technological innovation and world-class customer service. Specializing in mobile payments and value-added transactional services, the company has set itself apart as one of the fastest-growing companies in North America, according to Deloitte’s 2017 Technology Fast 500 and the South Florida Business Journal. This one-stop, omni-channel processing solution provides over 100 payment solutions. In North America, NETE’s transactions revenues rose over 17 percent year-over-year. Through the combination of organic growth, global merchants and innovative services, the company is positioned for continued expansion.

The company recently announced (http://ibn.fm/Oqntz) the launch of the Netevia in-app payments software development kit (SDK). The platform makes it possible for developers and hardware manufacturers to process payments with existing consumer-facing applications. The Netevia SDK is a feature-ready, multichannel platform that allows developers to build a secure, payment-card industry (PCI) and cryptocurrency-compliant experience for the user that simplifies payments through a single integration point.

Bain & Company predict that the global Internet of Things (IoT) market will reach $510 billion by 2021. When combined with Cisco’s estimate that more than 50 billion devices will be connected to the internet, it becomes clear that Netevia has a huge opportunity to reach a rapidly expanding market. The all-in-one platform, easy set-up and real-time reporting are only some of the features listed at www.Netevia.com.

According to Statista, worldwide mobile payment volume is expected to surpass $1 trillion in 2019. NETE is setting the standard for the industry while focusing on the creation of a unified global transaction acceptance ecosystem. The company believes that, by understanding consumer behavior and the needs of merchants, it can effectively power global commerce and equip clients to conduct business worldwide.

To achieve this goal and maintain its competitive edge, NETE is strategically focused on continued investment in core technology, new product offerings (such as the Netevia SDK), allocating resources and expertise to grow in commerce and payments segments, strategic acquisitions, continued improvement and operational excellence.

For more information, visit the company’s website at www.NetElement.com

• MCOA supports a variety of portfolio companies, which participate at different levels within the cannabis and hemp industries
• The company has CBD-derived product brand hempSMART as a primary portfolio holding
• MCOA provides turn-key services to the legal cannabis and hemp industries

Marijuana Company of America Inc. (OTCQB: MCOA) delivers recognized brands via innovative marketing distribution companies. MCOA is an umbrella company. It is undergoing development to support an array of portfolio companies that participate within the cannabis and hemp industries. Primarily an industrial hemp business, one of MCOA’s main companies is wholly owned subsidiary hempSMART Inc. Company management has expertise in cultivation, processing and distribution. MCOA has its corporate headquarters in Escondido, California.

The company provides turn-key services to the legal cannabis and hemp industries. Most of MCOA’s projects are involved in the cultivation and distribution of hemp-derived products. Its hempSMART subsidiary offers a line of industrial hemp-derived cannabidiol (CBD) products, which contain no THC. In addition, hempSMART offers the opportunity to distribute its products as part of its associate marketing model. In essence, MCOA’s focus is on hemp more than marijuana. It is targeting the $3.7 trillion wellness industry with branded cannabidiol products (http://ibn.fm/9Xm9z).

Grand View Research (http://ibn.fm/vFKSd) noted in a report, “The global industrial hemp market size was estimated at USD 3.9 billion in 2017, expanding at a CAGR of 14.0% over the forecast period.” It added (http://ibn.fm/yZZBn), “The global industrial hemp market size is expected to reach USD 10.6 billion by 2025.”

Moreover, Technavio, based on its industry analysis (http://ibn.fm/Mw33r), predicts that, “…the industrial hemp market will grow at a year-over-year rate of 15.3% in 2019, with a CAGR of 15.5% through to 2023.” Moreover, the expectation is that legal marijuana markets will reach $24.5 billion by 2021 (http://ibn.fm/4dw4O).

MCOA is leveraging this growth by establishing itself along different points in the industrial hemp, cannabis and related services supply chains (http://ibn.fm/jaGne). The company and joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) recently announced that clone production for the 2019 season at its Scio, Oregon, high yielding CBD hemp project is now very active in preparation for an “as early as possible” planting this year (http://ibn.fm/dGbRc).

Along with hempSMART, MCOA’s portfolio companies include Brunswick Hemp Project, Covered Bridge Acres LTD and MoneyTrac Technology. The company’s product portfolio, by way of hempSMART, includes hempSMART Brain, hempSMART Face, hempSMART Drops, hempSMART Pain Capsules and hempSMART Pain Cream. The company’s certificates of analysis validate the purity and quality of its THC-free products (http://ibn.fm/qryOB).

Furthermore, MCOA places an emphasis on the leasing of real property to separate business entities involved in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and appropriately regulated for medicinal and recreational use. The company additionally engages in the expansion of its business into supplementary areas of the legalized cannabis and hemp industries.

MCOA continues to work to create value for its shareholders. It is doing so with diverse initiatives, including strategically investing in synergistic companies to develop a varied portfolio of subsidiaries and JVs. MCOA envisions a future in which it will be a model for entrepreneurs and businesses that share its common goals and philosophies. This includes creating an environment for businesses to improve quality of life for their customers.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

• The market share of immunotherapy treatments for breast cancer and other malignancies is expected to increase exponentially by 2024
• The incidence of breast cancer is set to grow by 50 percent in the next decade
• BriaCell Therapeutics Corp. has already established the effectiveness of its lead candidate, Bria-IMT, in clinical trials
• A personalized, off-the-shelf immunotherapy solution, Bria-OTS, is under development

With the incidence of breast cancer expected to increase worldwide, the therapeutic market for this particular ailment is also set to grow at a CAGR of eight percent through 2023, according to industry reports (http://ibn.fm/HVYSA). Companies such as BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) will be leading the way, as the development of new treatment solutions is expected to be a primary factor contributing to the market’s growth.

According to the ‘Global Breast Cancer Therapeutics Market 2019-2023’ report, various innovative therapies are emerging to offer breast cancer patients more advanced solutions than the ones currently available. Therapies having the potential to address advanced breast cancer cases will also dominate the market in the years to come, the report concludes.

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, is currently testing such specialized therapies for advanced breast cancer patients. The company is developing immunotherapy solutions that have so far proven to be both highly effective and well-tolerated by patients.

Bria-IMT, the lead BriaCell cancer drug candidate, has delivered promising results in three clinical studies to date. In tests with advanced breast cancer patients, Bria-IMT contributed to tumor shrinkage. Currently, Bria-IMT’s effectiveness is being assessed in combination with KEYTRUDA (pembrolizumab) by Merck & Co., Inc. (NYSE: MRK).

Bria-IMT works by providing breast cancer antigens and stimulation of the T-cells – an important part of the immune system responsible for fighting cancer. Proof of concept for this therapy has already been achieved in clinical trials. Its safety has been established as excellent, even in the case of heavily-pretreated advanced breast cancer patients.

The combination study has treated six patients to date with Bria-IMT and KEYTRUDA. All patients tolerated the combination very well, and additional data about the efficacy of the combination will be released in the first quarter of 2019.

BriaCell Therapeutics Corp. is also working to develop Bria-OTS – a personalized, off-the-shelf immunotherapy solution for advanced breast cancer patients. Bria-OTS is expected to provide a tailor-made breast cancer solution that is much more cost-efficient and easier to manufacture than alternative treatments.

According to the company, the very same technology could be applicable to the treatment of other types of cancer.

Several studies indicate that the incidence of breast cancer is expected to increase in the next decade (http://ibn.fm/XR9CX). U.S. breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000 in 2030, an increase of over 50 percent. The proportion of cases diagnosed among women in the 50-to-69 age group is expected to decrease from 55 percent to 44 percent in 2030. Diagnoses among those aged 70 to 84, however, will increase from 24 percent to 35 percent.

Immunotherapy could provide a viable solution to the problem. The cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent (http://ibn.fm/IBQyc). Immunotherapy currently accounts for 50 percent of the oncology medications market, but it is forecast that roughly 60 percent of previously treated cancer patients will adopt immunotherapy by 2026.

With its dedicated immunotherapies, BriaCell Therapeutics Corp. is on the front line of the battle, exploring new ways to address the unmet medical needs of advanced cancer patients. The potential market is estimated to be between $1 billion and $5 billion, depending on the stage of treatment.

For more information, visit the company’s website at www.BriaCell.com

• Aziza Project’s security token offering permits token holders to share in company profits
• Aziza Project has an investment in Africa New Energies
• Its security token value comes from the value of assets held by the Aziza Project in Namibia

Aziza Project LLC offers cyber tokens backed by assets and invests in early-stage oil and gas exploration operations in the underdeveloped regions of Southern Africa. Its initial investment is a 20 percent stake in Africa New Energies (“ANE”). ANE is preparing to drill wells on a Montana-sized portion of Namibia. Aziza Project owns 20 percent of ANE. London-based Aziza Project is working to raise $60 million to complete a 10-well drilling program. It is doing so via the sale of Aziza Coin tokens, which it offered through a security token offering in October 2018 (http://ibn.fm/Fsxl6).

Crypto tokens are used to represent digital assets that are fungible (mutually interchangeable) and tradeable. These tokens are often hosted by another platform, such as the Ethereum blockchain, instead of operating on a blockchain of their own (http://ibn.fm/5ITkB). There are three types of crypto tokens: asset-backed tokens, currency or coin tokens (standalone cryptocurrencies based on their own blockchain) and utility tokens.

Aziza Project’s security token offering (backed by assets) will allow token holders to share in company profits. Its security token is a digital asset deriving its value from a tradeable external asset. Therefore, its value comes from the value of assets held by the Aziza Project, such as its investment in ANE and ANE’s considerable hydrocarbon asset in Africa. Coinmonks (http://ibn.fm/rg7ys) noted in a recent article that, “Even though the ecosystem is young and still developing, there’s incredible potential for security tokens to evolve and pave the way for an entirely new way of investing and raising capital.”

With Aziza Project’s significant investment in ANE, the proving of the oil and gas resource could result in the Aziza Project’s holdings being worth up to $621 million. There’s much to be positive about concerning oil and gas exploration in Africa. South Africa is advancing on boosting its oil and gas sector this year (http://ibn.fm/XNCwV). Furthermore, Uganda is lobbying for investors in its Albertine fields to prospect for oil, and the country is inviting new oil exploration bids (http://ibn.fm/K3sI8).

Namibia is ranked as being business and investor friendly. The nation is ranked “1= most business-friendly regulations” in the Ease of Doing Business Index by Trading Economics (http://ibn.fm/bdvSE). The Financial Times reported that interest in Namibia as an oil and gas region has picked up in recent years. It noted that Namibia has the same geological formations as Brazil, where pre-salt fields have attracted substantial investment (http://ibn.fm/334H0).

Fundamentally, Aziza Project is focusing on the ethical development of oil and gas. Its ANE initiative is a first-rate investment. ANE has title to a 22,000 square kilometer onshore prospective hydrocarbon concession in Namibia, as well as supportive airborne data and geochemical evidence of hydrocarbons (http://ibn.fm/SluV6). Hence, Aziza Project’s return on investment is expected to come from the successful completion of the 10-well drilling program. The success of this program is planned to help ANE finance the construction of a hybrid gas-to-solar power plant in the long term, which will supply low-cost electricity to the local grid.

The crypto industry is moving toward practical mainstream adoption and regulation. Aziza Project is leveraging this trend and offering investors a new way to partake in oil and gas initiatives in Southern Africa through its security tokens. With its cyber tokens and ANE investment, Aziza Project is on course for growth in investor-friendly Namibia.

For more information, visit the company’s website at www.Aziza.io

• Spectrum Global Solutions sees trading on OTCQB as a necessary next step in its continued development
• Demand for increased network capabilities is increasing as global use of data continues to grow exponentially
• Spectrum Global is set to reach this increased demand primarily through its multiple subsidiaries with regional, national and global projects

Spectrum Global Solutions Inc. (OTCQB: SGSI), a leading single-source provider of end-to-end, next-generation wireless and wireline networks, recently announced that its stock has been uplisted and approved for trading on the OTCQB Venture Marketplace. The company provides professional service solutions to the service provider and corporate enterprise markets.

CEO Roger Ponder described the benefits of trading on the OTCQB. He referred to it as an “established public market,” allowing only well-established companies to trade. The criteria for approval includes several components. Companies’ financial reporting must be up-to-date (http://ibn.fm/grBUY), and they must also “undergo an annual verification and management certification process.” Ponder sees the listing as a necessary step in the continued growth of Spectrum Global. In a news release, he mentioned, “As we focus on building a business that delivers long term shareholder value, we believe this up-listing will enhance investor accessibility and serve as a stepping stone to meet the listing requirements for admission to the NASDAQ or NYSE in the future.”

As more and more of the world’s citizens rely on their smartphones, tablets, and devices every day, mobile data traffic has skyrocketed, creating a global demand for increased network capabilities. The telecom industry expects to grow exponentially in coming years to meet this demand for better coverage, enhanced capability, private networks and swift development of new apps.

The industry has evolved from 2G in 1991 to 3G in 1998 and 4G in 2008, increasing the demand for quality wireless and wireline network providers and enhancing the overall revenue stream of such entities. Spectrum Global pledges, “We engineer, upgrade, install, and maintain next-generation telecommunication networks.” This type of service will become especially relevant in the coming years, as 5G is expected to be rolled out in 2020. According to Accenture (http://ibn.fm/i31Ux), “The 5G rollout will create 3 million American jobs and drive over $500 billion U.S. GDP growth.”

Spectrum Global owns and operates multiple subsidiaries, which allow it to provide comprehensive services covering all aspects of fiber networks and infrastructure. These subsidiaries include AW Solutions, LLC; ADEX Corporation, LLC; TNS, Inc.; and Tropical Communications, Inc. Through these subsidiaries, Spectrum Global has grown a project portfolio that extends regionally, nationally and globally. Its new trading position on the OTCQB will be crucial in supporting the company’s continued development.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

• LXRP subsidiary Lexaria Nicotine LLC enters definitive investment agreement with large tobacco company to receive R&D funding in exchange for licensing and equity
• Partner has provided initial $1 million – with an option for up to $11 million more – for research on DehydraTECH’s oral forms of nicotine delivery through a series of private financings
• LXRP still retains majority equity ownership of Lexaria Nicotine, while partner receives a minority equity interest in the subsidiary, not in LXRP itself

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH absorption platform will receive a significant injection of R&D financing under an investment agreement that wholly owned subsidiary Lexaria Nicotine LLC has entered into with a large tobacco partner. LXRP has initially received $1 million toward its research on nicotine consumer products that use DehydraTECH (http://ibn.fm/Kx7Cm).

Through the agreement, the partner also has the option to provide up to $11 million in additional research through multiple phased private financings to underwrite LXRP’s R&D. In exchange, the partner will receive certain license rights to commercialize these DehydraTECH products exclusively in the United States and non-exclusively elsewhere. The partner, the largest cigarette company in the U.S., will be obligated to pay LXRP a royalty on sales of all products that use DehydraTECH.

The partner will have the option to buy full ownership of LXRP’s subsidiary, but no equity in LXRP itself, per the terms of the agreement. Additionally, the partner will have the right to appoint one of the seven directors of LXRP, and, as the phased additional investments are made, it may have the right to appoint up to three directors.

Lexaria Nicotine plans to conduct a series of clinical investigations into oral forms of nicotine delivery using DehydraTECH technology. In a news release, John Docherty, LXRP president, said, “Lexaria Bioscience has repeatedly demonstrated the powerful effects of its patented DehydraTECH technology for enhancing the palatability and speed of onset of orally consumed bioactive substances such as nicotine.”

Based in British Columbia, Canada, LXRP is a biotechnology company and drug-delivery platform innovator focused on out-licensing its disruptive delivery technology, which promotes healthier ingestion methods. LXRP holds a patent for the oral delivery of all cannabinoids and has a growing IP portfolio that includes 10 patents granted in the United States and Australia, with more than 50 patent applications worldwide across 10 patent families. DehydraTECH is its proprietary absorption technology platform.

For more information, visit the company’s website at www.LexariaBioscience.com

• ETST partners with Iq2 to develop food supplement designed to improve brain function
• Clinched deal with Forzagen to distribute cannabinoid product line in Mexico and South America
• Developing CBD beverage to tap $12 billion market

Earth Science Tech Inc. (OTCQB: ETST) has done it again. In partnership with Iq2 Labs, the Florida-based biotechnology company is formulating a super food supplement designed to enhance brain function through an initiative that continues the ongoing drive to strengthen its position in the hemp-derived cannabinoid, nutraceutical, pharmaceutical and medical device markets (http://ibn.fm/802tg). The product, containing high-grade full-spectrum cannabinoids, is currently going through the package design process, after which it will be bottled, launched and plugged into ETST’s growing sales channels. The announcement by ETST comes on the heels of another: ETST has clinched a deal with premium dietary supplement provider Forzagen to distribute ETST’s line of cannabinoids throughout Mexico and South America (http://ibn.fm/HZAKY).

The partnership with Iq2 Labs and the introduction of the brain-boosting supplement – CBD Mental Clarity and Focus Shot – give ETST a foothold in the emerging CBD beverage market, according to Nickolas S. Tabraue, chairman of ETST. The high-grade full-spectrum cannabinoids produced in conjunction with Iq2 are expected to be an accretive addition to ETST’s line of products aiming to augment mental capacity and function. The company’s researchers continue their efforts to develop a CBD beverage utilizing the University of Central Oklahoma’s provisional patent to improve immune system functions (http://ibn.fm/KiZ40). An aspect of ETST’s marketing strategy focuses on increasing the ways it can deliver its CBD products to the marketplace. The collaboration with the University of Central Oklahoma, under the direction of Dr. Michel Aube, chief science officer of ETST, forms part of this plan.

Under a sponsored research agreement with the University of Central Oklahoma, tests were carried out to determine the effects of ETST’s CBD Cannabidiol Rich Hemp Oil on immune cells. The results were encouraging (http://ibn.fm/MwRi8). Research showed that ETST’s hemp oil solution, used in appropriate CBD concentrations, could, through the production of Tumor Necrosis Factor alpha (TNFα), stimulate macrophages, an important immune cell. The cytokine TNFα is a key cell signaler in the recruitment of immune cells. A robust immune system plays an important part in maintaining good health and may help fight cancer. There is now hope that the effects of hemp oil enriched with CBD on immune cells may be used to improve cancer treatment, particularly in combination with other treatment modalities. The proposed beverage will allow ETST to tap into the $11.7 billion (2018 estimate) CBD beverage market, which is projected to hit $25 billion by 2025.

With the establishment of these partnerships in 2019, ETST sustains the relentless path of growth put into place in 2018, when it doubled sales. ETST also uplisted to the OTCQB Venture Market and introduced a new product, Hygee, a non-invasive discreet chlamydia testing kit. The company continues to disrupt the hemp-derived cannabinoid, nutraceutical, pharmaceutical and medical device markets. Its activities range from R&D to production to marketing and distribution. ETST plans to keep building the networks and infrastructure to launch new subsidiaries and new products, like its super supplement to boost brainpower.

For more information, visit the company’s website at www.EarthScienceTech.com

• Net Element specializes in e-commerce technological solutions for an increasingly digital era
• Company’s Netevia platform rolls out new capability for Internet of Things marketplace with In-App Payments Software Development Kit
• Forecasts predict that IoT industry will produce more than 50 billion devices by 2020, with revenues of $520 billion by 2021

Online payment technology innovator Net Element Inc. (NASDAQ: NETE) has made its business the art of enabling commerce amid the digital finance revolution, and the company announced the further development of its Netevia B2B e-commerce services in a January 22 news release that highlights the launch of Netevia’s In-App Payments Software Development Kit (SDK) for hardware manufacturers and application developers building Internet of Things (IoT) connectivity (http://ibn.fm/dZnLS).

The Net Element platform’s SDK for IoT provides an avenue for developers to build a simple, professional payments flow protocol for IoT-networked devices that is fully compliant with payment card industry data standards. The SDK promotes a single integration point for the varied channels that have become such a feature of e-commerce in the mobile technology era, allowing businesses to pursue best practices efficiency in their transactions with consumer-facing tech.

Cryptocurrencies have become vital as a means of transcending the regulatory hurdles of cross-border commerce on a global scale, and the SDK for IoT includes payment acceptance for the blockchain-powered ecosystem.

“The Netevia Platform simplifies payments across multiple channels through a single point of integration,” Chief Technology Officer Andrey Krotov stated via the news release. “According to Visa, Inc., by 2020 there will be more than 50 billion devices connected to the Internet, providing a huge opportunity for these devices to include payments experience through Netevia SDK.”

The company also cites research by Bain & Company predicting that the global IoT market will more than double its 2017 revenues to $520 billion by 2021 – only a couple of years away, granting Net Element a sizable pie from which to grab a piece.

Net Element specializes in software that provides payment solutions as a service for business enterprises ranging from small to medium in size. The company’s Aptito tech solution supports point of sale transactions for restaurants and retailers, while VIP Payments supports the hotel and tourism industry and Unified Mobile Payments supports businesses on the go, such as kiosk and truck vendors.

For more information, visit the company’s website at www.NetElement.com

• The Supreme Cannabis Company’s business model allows it to control every stage of the process, from cultivation to distribution
• Its subsidiary, 7ACRES, operates a 440,000 square foot facility in Ontario, Canada – the largest facility of its kind to commercially cultivate cannabis
• The company recorded 71 percent revenue growth from Q3 to Q4 in its fiscal year ended June 30, 2018

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1), a key player in the medical and commercial cannabis industries, intends to become the largest commercial cannabis retailer worldwide through its focus on innovation and emphasis on product quality.

The Supreme Cannabis Company is seasoned in the cultivation of medical cannabis, though it grew out of humble origins after Peter Herburger began cultivating medical cannabis when his daughter, Sarah, became afflicted with chronic pain. Its subsidiary, 7ACRES, was federally licensed for production on March 11, 2016. After Canada legalized the production and sale of commercial cannabis, the company saw its opportunity to broaden its industry reach. It is currently the only licensed producer focused on cultivating craft quality cannabis on a commercial scale, and it has emerged as the industry leader in mass cultivation as a result of its high quality product.

With a passion for quality, the company seeks to excel at every stage of the cannabis industry. 7ACRES operates a 440,000 square foot facility in Ontario, Canada. It is currently the largest facility of its kind to cultivate cannabis with advanced HVAC and CO2 enrichment using the full-spectrum sun. Direct sunlight produces indoor-quality buds with sun-grown characteristics. This is in direct contrast to most “hybrid” growers, who typically used limited-spectrum lamps, and it is indicative of the company’s zest for quality in all stages of the business model, from production to distribution. The Supreme Cannabis Company continues to invest in research and innovation in order to maintain its peak position in the burgeoning cannabis industry.

The company is Canada’s only coast-to-coast premium cannabis producer, and it saw exponential revenue growth in 2018. After uplisting its shares to the OTCQX market in the U.S., the company reported record revenues of C$3.55 million, marking a 71 percent increase from Q3 to Q4. After reporting its revenues for its fiscal year ended June 30, The Supreme Cannabis Company earned its spot amongst the publicly traded Canadian cannabis companies with the highest revenue in their first four quarters of sales.

While varying degrees of cannabis legislation have trickled through the U.S. over the past year, the industry continues to grow worldwide. One recent development in California might mean even more growth for the industry (http://ibn.fm/DCSae). The state has “endorsed a rule allowing home marijuana deliveries statewide, even into communities that have banned commercial pot sales.” This development, along with others that are likely to follow, will continue to foster growth in the cannabis industry and create future footholds for businesses like The Supreme Cannabis Company to strengthen their staying power.

For more information, visit the company’s website at www.Supreme.ca